undamentalytics Newsletter
Sign in

Ultragenyx Pharmaceutical Inc. balance sheet

At the end of fiscal 2025, Ultragenyx Pharmaceutical Inc. had total assets of $1.53bn, total liabilities of $1.60bn and shareholders' equity of −$80.0m. It held $421m in cash against $0 of debt: net cash of $421m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents161100113434714308133214174421125
Receivables—5133323284073122158200
Inventory—171213162734455259
Total current assets4022705228511,295857884732817951606
Goodwill—44444444444444444444
Total assets5414917201,1351,7601,5221,5451,4911,5031,5321,264
Accounts payable59121313174342393139
Deferred revenue (current)—6——679—————
Total current liabilities607175103190181261280344384351
Total debt00000000000
Total liabilities671071114826056001,1931,2161,2411,6051,548
Shareholders' equity4743836096541,154923352275255−80−291
Net debt (negative = net cash)−161−100−113−434−714−308−133−214−174−421−125
Shares outstanding41m44m51m58m67m69m70m82m93m97m99m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NRIX vs RAREARWR vs RARERARE vs TGTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ultragenyx Pharmaceutical Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ultragenyx Pharmaceutical Inc.